JP2005519902A - 慢性的移植片拒絶反応の治療と予防のためのTGF−β拮抗薬の使用 - Google Patents
慢性的移植片拒絶反応の治療と予防のためのTGF−β拮抗薬の使用 Download PDFInfo
- Publication number
- JP2005519902A JP2005519902A JP2003561533A JP2003561533A JP2005519902A JP 2005519902 A JP2005519902 A JP 2005519902A JP 2003561533 A JP2003561533 A JP 2003561533A JP 2003561533 A JP2003561533 A JP 2003561533A JP 2005519902 A JP2005519902 A JP 2005519902A
- Authority
- JP
- Japan
- Prior art keywords
- tgf
- use according
- graft
- antagonist
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090001012 Transforming Growth Factor beta Proteins 0.000 title claims abstract description 154
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title claims abstract description 154
- 102000004887 Transforming Growth Factor beta Human genes 0.000 title claims abstract description 153
- 239000002876 beta blocker Substances 0.000 title claims abstract description 55
- 230000001684 chronic effect Effects 0.000 title claims abstract description 46
- 238000011282 treatment Methods 0.000 title claims description 17
- 206010052779 Transplant rejections Diseases 0.000 title claims description 9
- 230000002265 prevention Effects 0.000 title description 5
- 210000004072 lung Anatomy 0.000 claims abstract description 16
- 210000003734 kidney Anatomy 0.000 claims abstract description 15
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 13
- 230000001404 mediated effect Effects 0.000 claims abstract description 13
- 210000004185 liver Anatomy 0.000 claims abstract description 12
- 210000002216 heart Anatomy 0.000 claims abstract description 11
- 108010079292 betaglycan Proteins 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 49
- 239000013598 vector Substances 0.000 claims description 32
- 238000012546 transfer Methods 0.000 claims description 25
- 206010016654 Fibrosis Diseases 0.000 claims description 23
- 230000004761 fibrosis Effects 0.000 claims description 23
- 241000701161 unidentified adenovirus Species 0.000 claims description 18
- 239000005557 antagonist Substances 0.000 claims description 16
- 108091005735 TGF-beta receptors Proteins 0.000 claims description 15
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 108010029485 Protein Isoforms Proteins 0.000 claims description 8
- 102000001708 Protein Isoforms Human genes 0.000 claims description 8
- 102000016611 Proteoglycans Human genes 0.000 claims description 7
- 108010067787 Proteoglycans Proteins 0.000 claims description 7
- 230000011664 signaling Effects 0.000 claims description 7
- 102000004237 Decorin Human genes 0.000 claims description 5
- 108090000738 Decorin Proteins 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims description 4
- 102000004954 Biglycan Human genes 0.000 claims description 4
- 108090001138 Biglycan Proteins 0.000 claims description 4
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 claims description 4
- 108010036395 Endoglin Proteins 0.000 claims description 4
- 102100037241 Endoglin Human genes 0.000 claims description 4
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims description 4
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims description 4
- 102000011681 Lumican Human genes 0.000 claims description 4
- 108010076371 Lumican Proteins 0.000 claims description 4
- 102000003946 Prolactin Human genes 0.000 claims description 4
- 108010057464 Prolactin Proteins 0.000 claims description 4
- 102000005157 Somatostatin Human genes 0.000 claims description 4
- 108010056088 Somatostatin Proteins 0.000 claims description 4
- HXXFSFRBOHSIMQ-RWOPYEJCSA-L alpha-D-mannose 1-phosphate(2-) Chemical compound OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@@H](O)[C@@H](O)[C@@H]1O HXXFSFRBOHSIMQ-RWOPYEJCSA-L 0.000 claims description 4
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 4
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 4
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 229940097325 prolactin Drugs 0.000 claims description 4
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 4
- 229960000553 somatostatin Drugs 0.000 claims description 4
- 102000017177 Fibromodulin Human genes 0.000 claims description 3
- 108010013996 Fibromodulin Proteins 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 210000004204 blood vessel Anatomy 0.000 claims description 3
- 102000013361 fetuin Human genes 0.000 claims description 3
- 108060002885 fetuin Proteins 0.000 claims description 3
- 210000003709 heart valve Anatomy 0.000 claims description 3
- 230000008595 infiltration Effects 0.000 claims description 3
- 238000001764 infiltration Methods 0.000 claims description 3
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 2
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 210000000056 organ Anatomy 0.000 abstract description 42
- 238000000034 method Methods 0.000 abstract description 27
- 230000014509 gene expression Effects 0.000 abstract description 20
- 239000000835 fiber Substances 0.000 abstract description 6
- 238000011065 in-situ storage Methods 0.000 abstract description 5
- 206010006448 Bronchiolitis Diseases 0.000 abstract description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract description 4
- 230000012010 growth Effects 0.000 abstract description 4
- 230000000414 obstructive effect Effects 0.000 abstract description 4
- 238000002054 transplantation Methods 0.000 description 36
- 230000000694 effects Effects 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 20
- 230000006870 function Effects 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000003176 fibrotic effect Effects 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 208000000884 Airway Obstruction Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 108700019146 Transgenes Proteins 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 150000007523 nucleic acids Chemical group 0.000 description 5
- 210000000496 pancreas Anatomy 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 206010062016 Immunosuppression Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 3
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000005745 host immune response Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000011694 lewis rat Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 238000013425 morphometry Methods 0.000 description 3
- -1 oily media Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241001135569 Human adenovirus 5 Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010053159 Organ failure Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000011316 allogeneic transplantation Methods 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000011685 brown norway rat Methods 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 230000000893 fibroproliferative effect Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 238000012637 gene transfection Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical group 0.000 description 2
- 239000013605 shuttle vector Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 241000415078 Anemone hepatica Species 0.000 description 1
- 206010003162 Arterial injury Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 244000148064 Enicostema verticillatum Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- 101100334471 Schizosaccharomyces pombe (strain 972 / ATCC 24843) fib1 gene Proteins 0.000 description 1
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 1
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 description 1
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 1
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 description 1
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 1
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 244000291414 Vaccinium oxycoccus Species 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001953 common bile duct Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 101150030247 fib gene Proteins 0.000 description 1
- 230000003352 fibrogenic effect Effects 0.000 description 1
- 101150076530 flpA gene Proteins 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011085 pressure filtration Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 210000005092 tracheal tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000010024 tubular injury Effects 0.000 description 1
- 208000037978 tubular injury Diseases 0.000 description 1
- 230000010248 tubular secretion Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本発明は、分子生物学および臓器移植の分野における発明である。本発明はTGF-βの有効な阻害剤の使用による、移植された臓器または組織の拒絶反応を治療または予防する新規な方法に向けられる。
臓器移植は疾患または傷害に起因する臓器機能の損失に直面した患者に重要な治療になっている。米国では、例えば、1997年1月から1998年12月の間に(即ち、完全な3年の追跡統計のある最も最近の期間)、1600件を超す肺移植、4000件を超す心臓移植、7000件を超す肝臓移植、400件を超す膵臓移植、および22000件を超す腎臓移植が行われた。
本発明者らは、線維症があらゆる型の臓器移植片の慢性拒絶反応における共通の因子であること、およびTGF-βが線維症による慢性拒絶反応において上昇することが多い(他の多くの因子と共に)ことに注目した。例えば、肺移植において、移植後のTGF-βのアップレギュレーションに相関する線維増殖は閉塞性細気管支炎として知られている小気道の線維性破壊につながる(例えば、Charpinら、Transplantation, 65(5): 752-755; El-Gamelら、1998, Eur. J. Cardiothorac. Surg., 13(4): 424-30参照);腎移植では、腎移植片機能の低下につながる管状間隙(tubulointerstitium)の線維症がTGF-βの発現の増加および尿中へのTGF-βの分泌に相関した(例えば、Cuhaciら、1999, Transplantation, 68(6): 785-790; Boratynska, 1999, Ann. Transplant., 4(2): 23-28);心臓移植では、総TGF-βおよび内因性TGF-βの発現(mRNA)がアテローム性動脈硬化の急速な進展に相関する例がみられる(Littleら、1999, Transpl. Int, 12(6): 393-401);ならびに肝臓再生では、TGF-βは肝細胞増殖の阻害剤であり、かつ慢性肝疾患で線維症を誘発すると考えられている(例えば、Faustoら、1991, Ciba Found. Symp., 157: 165-174; Discussion 174-7)。
本明細書の開示は、TGF-β介在線維増殖による移植片臓器の慢性的破壊を遮断するためのTGF-β拮抗薬の有効な使用を記載する最初の報告である。本明細書に示されたように、TGF-β拮抗薬は移植片機能の損失を予防および低減するのに有用である。本明細書において、移植臓器の慢性的拒絶反応が、TGF-β活性を直接阻害するTGF-β拮抗薬の投与によって阻止できることが始めて実証された。従って、本発明は、移植臓器、特に肺、心臓、腎臓、膵臓、および肝臓の同種移植の慢性的拒絶反応を予防または遅延する方法を提供する。本発明は、慢性的拒絶反応の主要指標であるが、通常移植片の拒絶反応または不全が避けられない場合に検出される指標である、移植片組織における破壊性線維症を阻止する方法を提供する。
TGFB拮抗薬の遺伝子移入のためのアデノウイルスベクターの調製
ヒトTGF-βIII型可溶性受容体を、クローン番号7411(クローン番号7411はWhitehead InstituteのLodish/Weinberg labsから入手した)(Morenら、Biochem Biophys. Research Communication, 189:356-362 (1992))から以下のプライマー
を用いてVentR(商標)DNAポリメラーゼ(New England Biolabs, Beverly,MA)によって増幅した。PCR産物は、1 %アガロースゲル上で分画し、2.2kb産物を精製し、Ecl136IIおよびXba Iで消化し、pAdQUICK(以前はpAdvantageと呼ばれた)シャトルベクターpSV2-ICEU I(Genzyme社、 Cambridge, MA)のEcoR V-Xba I部位にクローニングした。組換えアデノウイルは、Souzaら、1999, Biotechniques, 26:502-8の図1に説明される多段階方式で作製した。この迅速なクローニング系は3つの段階を含む:1) 導入遺伝子をシャトルベクターpSV2-ICEU Iにクローニングする。2) 次いで、それをpSV2-Ceu Iから消化によって、ウイルスベクターpAdQUICKのI-Ceu I部位にサブクローニングする。3) 次いで、pAdQUICKベースの組換えアデノウイルベクターをSnaBIで切断し、逆方向末端反復を曝露する。導入遺伝子発現を、ヤギ抗ヒトTGFBIIIR抗体(R & D Systems, Minneapolis, MN)をプローブとしたウエスタンブロティングを用いて、組換えアデノウイルスAd2TGFBIIIRで感染させた相補293細胞(アデノウイル5型 (Ad5), ATCC CRL-1573, Rockville, MD)によって形質転換した初代ヒト胚性腎細胞)の上清を試験して確認した。
雄のBrown-Norway および Lewisラット(約200-300 g)をそれぞれHarlan Sprague Dawley社(Indianapolis、IN)およびCharles River Canada社(St. Constant, Quebec, Canada)から購入した。動物の飼育はNIHガイドラインに従って提供され、Toronto General Hospital Research institute Animal Care Committeeで承認された。
移植後各時点でのTGF-βの発現
肺同種移植で発症する線維性気道閉塞は3相の時間経過に従う:即ち、最初の虚血相、それに続く完全な上皮損失を伴った顕著な細胞性浸潤相、および最後の同種移植気道管腔の線維性閉塞相である。Boehlerら、1997, Transplantation, 64: 311-317参照。浸潤細胞は主にリンパ球とマクロファージ、特にCD4+単核細胞である。
各時点におけるTGF-β拮抗薬遺伝子の移入
線維性気道閉塞における可溶性TGFBIIIRのアデノウイルス介在性遺伝子移入の影響を試験するために、可溶性TGFBIIIR遺伝子を含む組換えアデノウイルス(5×109粒子)を、移植当日(D0)、移植後5日目(D5)、および移植後10日目(D10)の3つの異なる時点で局所注入(レシピエントのLewisラットの同種移植部位での注入)することにより投与した。結果を図2に示す。気道閉塞は未処理対照(CO)と比較して、D0群でやや阻害されたがD5群でより阻害の程度が大きかった。
阻害および投与経路
アデノウイルス介在性可溶性TGFBIIIR遺伝子移入の筋肉内注入と局所注入とを共に試験した。可溶性TGFBIIIR遺伝子を含むアデノウイルスベクターを、同種移植後5日目に局所的(気管移植部位に)または筋肉内(TGまたはIMG)注入した。空ベクターを含む組換えアデノウイルスを陰性対照(TV--空ベクター、局所注入;IMV--空ベクター、筋肉内注入)として用いた。未処理対照群(CO)も用いた。結果を図3に示す。可溶性TGFBIIIRの局所遺伝子トランスフェクション(群TG)は管腔の開存性を21日目まで保ったが、他のすべての群は殆ど完全な線維性管腔閉塞を示した(図3と図4)。気管構造の検査で、局所遺伝子移入は気道管腔の線維性閉塞を防止したが、上皮ライニング全体(すべての群で同じであった)の損失は遺伝子移入によっては防止できなかった。更に、上皮下空間に僅かな程度の線維増殖が観察され、その場所の正常な構造物に置き換わった。
Claims (38)
- 移植片におけるTGF-β介在線維症によって特徴づけられる慢性的な移植片拒絶反応の治療のための、薬学的組成物調製への有効量のTGF-β拮抗薬の使用。
- 慢性的な拒絶反応がレシピエントのTGF-β陽性細胞の移植片への浸潤によって特徴づけられることを特徴とする、請求項1記載の使用。
- 移植片が肺であることを特徴とする、請求項1または2記載の使用。
- 移植片が腎臓であることを特徴とする、請求項1または2記載の使用。
- 移植片が心臓であることを特徴とする、請求項1または2記載の使用。
- 移植片が肝臓または肝臓の一部であることを特徴とする、請求項1または2記載の使用。
- 移植片が心臓の弁であることを特徴とする、請求項1または2記載の使用。
- 移植片が血管の切片であることを特徴とする、請求項1または2記載の使用。
- 移植片が同種移植片であることを特徴とする、請求項1または2記載の使用。
- 移植片が異種移植片であることを特徴とする、請求項1または2記載の使用。
- 移植片レシピエントがヒトであることを特徴とする、請求項1または2記載の使用。
- TGF-β拮抗薬が、TGF-βの1つまたは複数のアイソフォームに対して向けられた抗体、TGF-β受容体、TGF-β受容体の1つまたは複数に対して向けられた抗体、潜伏関連ペプチド、大きな潜伏性TGF-β、TGF-β阻害プロテオグリカン、ソマトスタチン、マンノース−6−ホスフェート、マンノース−1−ホスフェート、プロラクチン、インスリン様成長因子II、IP−10、arg-gly-asp含有ペプチド、植物、真菌、細菌抽出物、アンチセンスオリゴヌクレオチド、およびTGF-βシグナル伝達に関与するタンパク質からなる群より選択される、請求項1または2記載の使用。
- TGF-β阻害プロテオグリカンが、フェチュイン、デコリン、バイグリカン、フィブロモジュリン、ルミカン、およびエンドグリンからなる群より選択されることを特徴とする、請求項12記載の使用。
- TGF-βシグナル伝達に関与するタンパク質が、SMAD、MAD、Ski、およびSnoからなる群より選択されることを特徴とする、請求項12記載の使用。
- TGF-βの1つまたは複数のアイソフォームに対して向けられた抗体がモノクロナール抗体ID11.16のヒトまたはヒト化された形態であることを特徴とする、請求項12記載の使用。
- 拮抗薬が、レシピエントにおいて拮抗薬をコードしている遺伝子を発現する事ができる遺伝子移入ベクターを介して投与されることを特徴とする、請求項12記載の使用。
- 遺伝子移入ベクターが、組換えアデノウイルスであることを特徴とする、請求項16記載の使用。
- 遺伝子が、TGF-β受容体またはTGF-βに結合可能なその断片をコードすることを特徴とする、請求項17記載の使用。
- TGF-β受容体がTGF-βIII型受容体であることを特徴とする、請求項17記載の使用。
- 移植片レシピエントにおける移植片機能の損失の治療のための、薬学的組成物調製への有効量のTGF-β拮抗薬の使用。
- 移植片機能の損失が、レシピエントのTGF-β陽性細胞の移植片への浸潤によって特徴づけられることを特徴をする、請求項20記載の使用。
- 移植片が肺であることを特徴とする、請求項20または21記載の使用。
- 移植片が腎臓であることを特徴とする、請求項20または21記載の使用。
- 移植片が心臓であることを特徴とする、請求項20または21記載の使用。
- 移植片が肝臓の一部であることを特徴とする、請求項20または21記載の使用。
- 移植片が心臓の弁であることを特徴とする、請求項20または21記載の使用。
- 移植片が血管の切片であることを特徴とする、請求項20または21記載の使用。
- 移植片が同種移植片であることを特徴とする、請求項20または21記載の使用。
- 移植片が異種移植片であることを特徴とする、請求項20または21記載の使用。
- レシピエントがヒトであることを特徴とする、請求項20または21記載の使用。
- TGF-β拮抗薬が、TGF-βの1つまたは複数のアイソフォームに対して向けられた抗体、TGF-β受容体、TGF-β受容体の1つまたは複数に対して向けられた抗体、潜伏関連ペプチド、大きな潜伏性TGF-β、TGF-β阻害プロテオグリカン、ソマトスタチン、マンノース−6−ホスフェート、マンノース−1−ホスフェート、プロラクチン、インスリン様成長因子II、IP−10、arg-gly-asp含有ペプチド、植物、真菌、細菌抽出物、アンチセンスオリゴヌクレオチド、およびTGF-βシグナル伝達に関与するタンパク質からなる群より選択されることを特徴をする、請求項20または21記載の使用。
- TGF-β阻害プロテオグリカンが、フェチュイン、デコリン、バイグリカン、フィブロモジュリン、ルミカン、およびエンドグリンからなる群より選択されることを特徴とする、請求項31記載の使用。
- TGF-βシグナル伝達に関与するタンパク質が、SMAD、MAD、Ski、およびSnoからなる群より選択されることを特徴とする、請求項31記載の使用。
- TGF-βの1つまたは複数のアイソフォームに対して向けられた抗体が、ヒトまたはヒト化モノクロナール抗体ID11.16のヒトまたはヒト化された形態であることを特徴とする、請求項31記載の使用。
- 拮抗薬が、レシピエントにおいて拮抗薬をコードしている遺伝子を発現する事ができる遺伝子移入ベクターを介して投与されることを特徴とする、請求項31記載の使用。
- 遺伝子移入ベクターが組換えアデノウイルスであることを特徴とする、請求項35記載の使用。
- 遺伝子が、TGF-β受容体またはTGF-βに結合することができる可能なその断片をコードしていることを特徴とする、請求項36記載の使用。
- TGF-β受容体がTGF-βIII型受容体であることを特徴とする、請求項37記載の使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35052902P | 2002-01-22 | 2002-01-22 | |
PCT/US2003/001726 WO2003061587A2 (en) | 2002-01-22 | 2003-01-21 | USE OF TGF-β ANTAGONISTS TO TREAT OR TO PREVENT CHRONIC TRANSPLANT REJECTION |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005519902A true JP2005519902A (ja) | 2005-07-07 |
JP4564261B2 JP4564261B2 (ja) | 2010-10-20 |
Family
ID=27613397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003561533A Expired - Fee Related JP4564261B2 (ja) | 2002-01-22 | 2003-01-21 | 慢性的移植片拒絶反応の治療と予防のためのTGF−β拮抗薬の使用 |
Country Status (7)
Country | Link |
---|---|
US (2) | US20030180301A1 (ja) |
EP (1) | EP1478354A4 (ja) |
JP (1) | JP4564261B2 (ja) |
AU (1) | AU2003209308A1 (ja) |
BR (1) | BRPI0307070A2 (ja) |
CA (1) | CA2473829A1 (ja) |
WO (1) | WO2003061587A2 (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2388441A1 (en) * | 2002-06-10 | 2003-12-10 | Wei-Ping Min | Immunomodulation using rna interference |
DK1755674T3 (en) | 2004-05-14 | 2015-02-09 | Alexion Pharma Inc | PROLONGED SURVIVAL OF A allograft by inhibiting complement activity |
EP1809324A4 (en) * | 2004-10-13 | 2009-02-25 | Univ Ohio State Res Found | METHODS OF TREATING OR PREVENTING LYMPHOPROLIFERATIVE DISORDERS ASSOCIATED WITH VIRUSES |
MX2008011054A (es) | 2006-03-02 | 2009-03-03 | Alexion Pharma Inc | Prolongacion de supervivencia de un aloinjerto, mediante la inhibicion de actividad de complemento. |
US20100098668A1 (en) * | 2006-09-29 | 2010-04-22 | Northshore University Health System | Oncolytic Adenoviruses and Uses Thereof |
PL2083863T3 (pl) * | 2006-10-03 | 2015-08-31 | Genzyme Corp | Przeciwciała przeciwko TGF-beta do stosowania w leczeniu niemowląt obarczonych ryzykiem rozwinięcia się dysplazji oskrzelowo-płucnej |
WO2011006029A1 (en) * | 2009-07-10 | 2011-01-13 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Artificial cell constructs for inducing immunological tolerance |
WO2012106634A1 (en) | 2011-02-03 | 2012-08-09 | Alexion Pharmaceuticals, Inc. | Use of an anti-cd200 antibody for prolonging the survival of allografts |
MX365385B (es) | 2013-03-11 | 2019-05-31 | Genzyme Corp | Anticuerpos anti-tgf-beta modificados genéticamente y fragmentos de unión a antígeno. |
CA2920293A1 (en) | 2013-08-16 | 2015-02-19 | Alexion Pharmaceuticals, Inc. | Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant |
EP3036262A4 (en) | 2013-08-22 | 2017-03-01 | Acceleron Pharma Inc. | Tgf-beta receptor type ii variants and uses thereof |
CN108348578B (zh) | 2015-08-04 | 2022-08-09 | 阿塞勒隆制药公司 | 用于治疗骨髓增生性病症的方法 |
EP4241848A3 (en) | 2017-05-04 | 2023-11-01 | Acceleron Pharma Inc. | Tgf-beta receptor type ii fusion proteins and uses thereof |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5705609A (en) * | 1988-06-28 | 1998-01-06 | La Jolla Cancer Research Foundation | Decorin fragments inhibiting cell regulatory factors |
US5654270A (en) * | 1988-06-28 | 1997-08-05 | La Jolla Cancer Research Foundation | Use of fibromodulin to prevent or reduce dermal scarring |
AU633011B2 (en) * | 1988-06-28 | 1993-01-21 | La Jolla Cancer Research Foundation | Suppression of cell proliferation by decorin |
US5571714A (en) * | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
EP0610427B1 (en) * | 1991-10-31 | 2003-04-02 | Whitehead Institute For Biomedical Research | Tgf-beta type iii receptor, cdna encoding it and uses therefor |
US6008011A (en) * | 1991-10-31 | 1999-12-28 | Whitehead Institute For Biomedical Research | TGF-β type II receptor cDNAs |
DE69228700T2 (de) * | 1991-12-04 | 1999-09-09 | Jolla Cancer Res Found | Verwendung von Decorin oder Biglycan zur Herstellung eines Medikaments für die Behandlung von Diabetes-bedingter Zustände |
GB9205800D0 (en) * | 1992-03-17 | 1992-04-29 | British Tech Group | Treatment of fibrotic disorders |
AU3943793A (en) * | 1992-04-01 | 1993-11-08 | Whittier Institute For Diabetes And Endocrinology, The | Methods of inhibiting or enhancing scar formation in the CNS |
US5869462A (en) * | 1992-09-10 | 1999-02-09 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of proliferation of vascular smooth muscle cell |
US5821234A (en) * | 1992-09-10 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of proliferation of vascular smooth muscle cell |
CA2146973C (en) * | 1992-10-29 | 2008-09-02 | Patricia R. Segarini | Uses of tgf-.beta. receptor fragment as a therapeutic agent |
US5830847A (en) * | 1992-10-30 | 1998-11-03 | Hsc Research & Development Limited Partnership | Soluble TGF-β-binding endoglin polypeptides and homodimers |
WO1995000103A2 (en) * | 1993-06-15 | 1995-01-05 | Il-Yang Pharm. Co., Ltd. | Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof |
EP0758452B1 (en) * | 1994-05-04 | 2001-11-07 | Mount Sinai Hospital Corporation | Modulators of cytokines of the tgf-beta superfamily and methods for assaying for same |
US5772995A (en) * | 1994-07-18 | 1998-06-30 | Sidney Kimmel Cancer Center | Compositions and methods for enhanced tumor cell immunity in vivo |
CA2156767A1 (en) * | 1994-08-25 | 1996-02-26 | Kenichi Matsunaga | Binding agent for growth factor |
US5834248A (en) * | 1995-02-10 | 1998-11-10 | Millennium Pharmaceuticals Inc. | Compositions and methods using rchd534, a gene uregulated by shear stress |
US5824655A (en) * | 1995-02-15 | 1998-10-20 | The University Of Utah | Anti-transforming growth factor-β gene therapy |
US5948639A (en) * | 1997-04-10 | 1999-09-07 | Millennium Pharmaceuticals, Inc. | TGF-β pathway genes |
AU771635B2 (en) * | 1999-01-05 | 2004-04-01 | American National Red Cross, The | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
-
2003
- 2003-01-21 JP JP2003561533A patent/JP4564261B2/ja not_active Expired - Fee Related
- 2003-01-21 EP EP03707462A patent/EP1478354A4/en not_active Withdrawn
- 2003-01-21 BR BRPI0307070-0A patent/BRPI0307070A2/pt active Search and Examination
- 2003-01-21 US US10/348,665 patent/US20030180301A1/en not_active Abandoned
- 2003-01-21 AU AU2003209308A patent/AU2003209308A1/en not_active Abandoned
- 2003-01-21 WO PCT/US2003/001726 patent/WO2003061587A2/en active Application Filing
- 2003-01-21 CA CA002473829A patent/CA2473829A1/en not_active Abandoned
-
2009
- 2009-05-20 US US12/469,554 patent/US20090263389A1/en not_active Abandoned
Non-Patent Citations (4)
Title |
---|
JPN6008052431, Hallscheidt, P, et al., Transplantation proceedings, 2001, Vol.33, pp.2157−2159 * |
JPN6008052435, Chemical Abstracts, 1998, Vol.129, No.11, p.118 * |
JPN6008052437, El−Gamel, A. et al., The Journal of Heart and Lung Transplantation, 1998, Vol.18, pp.828−837 * |
JPN6008052442, Hutchinson, I.V., Transplantation Proceedings, 1999, Vol.31, (Suppl.7A), pp.9S−13S * |
Also Published As
Publication number | Publication date |
---|---|
US20090263389A1 (en) | 2009-10-22 |
AU2003209308A1 (en) | 2003-09-02 |
WO2003061587A2 (en) | 2003-07-31 |
US20030180301A1 (en) | 2003-09-25 |
EP1478354A2 (en) | 2004-11-24 |
JP4564261B2 (ja) | 2010-10-20 |
CA2473829A1 (en) | 2003-07-31 |
WO2003061587A3 (en) | 2004-01-15 |
BRPI0307070A2 (pt) | 2019-03-26 |
EP1478354A4 (en) | 2008-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090263389A1 (en) | Use of TGF-Beta Antagonists to Treat or to Prevent Chronic Transplant Rejection | |
AU2007328206B2 (en) | Conjoint therapy for treating fibrotic diseases | |
CA2909356C (en) | Medical use of syndecan-2 | |
JP3854307B2 (ja) | 細胞外マトリックスの蓄積を防止するためのトランスフォーミング増殖因子βの阻害 | |
RU2599448C2 (ru) | Средства для стимуляции регенерации тканей путем привлечения мезенхимных стволовых клеток и/или плюрипотентных стволовых клеток костного мозга в кровь | |
EP2548578B1 (en) | Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases | |
JP3763479B2 (ja) | 生物学的に活性なTGF−β1およびTGF−β2ペプチド | |
Antoniou et al. | Pathogenetic pathways and novel pharmacotherapeutic targets in idiopathic pulmonary fibrosis | |
KR19980702268A (ko) | 항-형질전이 성장인자-β 유전자 요법 | |
EP1263464B1 (en) | Use of antagonist anti-tgf-beta antibodies to treat or to prevent loss of renal function | |
US7928068B2 (en) | Methods for using GEP, a chondrogenic growth factor and target in cartilage disorders | |
Lan et al. | Xenoextracellular matrix-rosiglitazone complex-mediated immune evasion promotes xenogenic bioengineered root regeneration by altering M1/M2 macrophage polarization | |
KR20180073692A (ko) | 성장 인자, 콘드로이틴 및 글루코사민을 포함하는 퇴행성 디스크 재생을 위한 조성물 및 방법 | |
US20050054563A1 (en) | Methods of treatment using wisp polypeptides | |
AU2002224377A1 (en) | Methods of Treatment Using WISP Polypeptides | |
Li et al. | TGF‐β1 peptide‐based inhibitor P144 ameliorates renal fibrosis after ischemia–reperfusion injury by modulating alternatively activated macrophages | |
WO2001002003A1 (en) | Method of treating psoriasis with il-15 antagonist | |
US20210388041A1 (en) | Compositions and methods for treating or preventing fibrosis | |
WO2024011946A1 (en) | Polypeptide dimers for the treatment of systemic sclerosis | |
Chen et al. | CC Motif Chemokine 2 Regulates Macrophage Polarization and Contributes to Myocardial Infarction Healing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050907 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20050907 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081016 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090113 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090120 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090212 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090219 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090312 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090319 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090416 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090514 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090812 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090819 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090929 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100707 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100730 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130806 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |